Complement receptor 2 targeted complement modulators
AssigneesMUSC Foundation for Research Development, The Regents of the University of Colorado
InventorsStephen Tomlinson, V. Michael Holers
Life of this patent
Estimating the term…
Abstract
Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.
Claims12
A composition comprising a construct, wherein the construct comprises:
- (a) a complement receptor 2 (CR2) or a fragment thereof, wherein the fragment contains at least the first two N-terminal short consensus repeat (SCR) domains of the CR2 protein;
- and
- (b) a modulator of complement activity, wherein the modulator comprises CD59.
A nucleotide sequence encoding a fusion protein comprising:
- (a) a complement receptor 2 (CR2) or a fragment thereof, wherein the fragment contains at least the first two N-terminal short consensus repeat (SCR) domains of the CR2 protein;
- and (b) a modulator of complement activity, wherein the modulator comprises CD59.
Dependencies are inferred from the claim text.